← Back to Home

Enimmune partners with Duopharma to bring enterovirus 71 vaccine to Malaysia and two other countries

EnVAX-A71 has secured an exclusive distribution partner for three Southeast Asian countries, but regulatory approval and procurement hurdles remain before it can enter local vaccination markets. The agreement includes no upfront payment or royalties, and revenue will depend on approval timelines and actual orders.

By SURL BioNews

For a vaccine to cross borders, it needs more than the product itself: someone must also take responsibility for regulatory applications, sales and supply. Taiwan’s Enimmune and Malaysia’s Duopharma Biotech announced a partnership on October 15 to establish a commercial pathway for the enterovirus 71 vaccine EnVAX-A71 in Malaysia, Singapore and Brunei. Whether it becomes a local prevention option will depend on regulatory reviews and market introduction in each country.

According to Enimmune’s material information disclosure, Duopharma subsidiary Duopharma (M) Sendirian Berhad has obtained exclusive distribution rights for the monovalent vaccine in the three countries and will undertake the regulatory requirements for marketing approval and annual minimum purchase obligations. Duopharma’s press release focuses primarily on Malaysia; Enimmune’s disclosure and the stock exchange filing cited by The Edge Malaysia explicitly identify all three licensed markets.

The medical significance of this partnership needs to be understood in terms of the virus type the vaccine covers. Enterovirus 71 (EV71, also known as A71) is one of the enteroviruses that can cause neurological complications in young children, but hand, foot and mouth disease can be caused by different types. EnVAX-A71 targets EV71 and should not be regarded as a vaccine covering all pathogens that cause hand, foot and mouth disease. This announcement also provides no new clinical efficacy or safety results.

The launch timeline also remains uncertain. The Edge Malaysia reported that Duopharma’s subsidiary is responsible for obtaining approvals in the three countries, while Enimmune will cover costs related to Good Manufacturing Practice (GMP) assessments and support launch marketing in Malaysia. Under the terms cited by the publication, the agreement in each market runs until the fifth anniversary of the local launch date; if a country refuses approval, the corresponding obligations for that country terminate. The five-year partnership described in the press release therefore needs to be read alongside the launch conditions in each market.

The transaction’s revenue structure is also clear. Enimmune said the agreement provides for no upfront payment, milestone payments or royalties. Actual revenue will depend on approval dates, orders and contract performance, and a definite financial impact cannot currently be reasonably estimated. The purchase commitments also include an exit condition: according to The Edge Malaysia, Enimmune has the right to terminate the agreement if order volumes fall below 70% of the annual minimum for two consecutive contract years.

With the partnership facilitated by the Biotechnology and Pharmaceutical Industries Promotion Office under Taiwan’s Ministry of Economic Affairs, the two companies are also looking toward future vaccine products. Duopharma said it may explore local manufacturing in Malaysia in the future, provided demand is sufficient and it is commercially viable; this is currently not a confirmed plan to establish a manufacturing facility. The more concrete tasks at hand remain completing regulatory procedures and connecting with public- and private-sector procurement, gradually turning distribution rights into vaccines available for supply.

References

  1. markets.businessinsider.com
  2. Duopharma Biotech Berhad
  3. The Edge Malaysia
  4. MoneyDJ — reproduction of Enimmune’s material information disclosure